首页> 外文期刊>Clinical & developmental immunology. >Mesenchymal Stem Cells Immunosuppressed IL-22 in Patients with Immune Thrombocytopenia via Soluble Cellular Factors
【24h】

Mesenchymal Stem Cells Immunosuppressed IL-22 in Patients with Immune Thrombocytopenia via Soluble Cellular Factors

机译:通过可溶性细胞因子免疫抑制血小板减少症患者间充质干细胞免疫抑制IL-22

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Mesenchymal stem cells are immunoregulation cells. IL-22 plays an important role in the pathogenesis of immune thrombocy-topenia. However, the effects of mesenchymal stem cells on IL-22 production in patients with immune thrombocytopenia remain unclear. Flow cytometry analyzed immunophenotypes of mesenchymal stem cells; differentiation of mesenchymal stem cells was observed by oil red O and Alizarin red S staining; cell proliferation suppression was measured with MTS; IL-22 levels of cell-free supernatants were determined by ELISA. Mesenchymal stem cells inhibited the proliferation of activated CD4+T cells; moreover, mesenchymal stem cells immunosuppressed IL-22 by soluble cellular factors but not PGE2. These results suggest that mesenchymal stem cells may be a therapeutic strategy for patients with immune thrombocytopenia.
机译:间充质干细胞是免疫调节细胞。 IL-22在免疫性血小板减少症的发病机理中起重要作用。然而,间充质干细胞对免疫性血小板减少症患者IL-22产生的影响尚不清楚。流式细胞仪分析了间充质干细胞的免疫表型;通过油红O和茜素红S染色观察到间充质干细胞的分化。用MTS测量细胞增殖抑制;通过ELISA测定无细胞上清液的IL-22水平。间充质干细胞抑制活化的CD4 + T细胞的增殖。此外,间质干细胞通过可溶性细胞因子而非PGE2免疫抑制IL-22。这些结果表明,间充质干细胞可能是免疫性血小板减少症患者的治疗策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号